Moreover, patients with EGFR/TP53/RB1-mutant lung cancers at diagnosis are at an increased risk of developing SCLC transformation, discontinuing EGFR-TKIs sooner, and a decreased OS [12]. The gene discussed is TP53; the disease is small cell lung carcinoma.